Publication: CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
Loading...
Open/View Files
Date
2015
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Sengupta, S., R. Rojas, A. Mahadevan, E. Kasper, and S. Jeyapalan. 2015. “CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer.” Oxford Medical Case Reports 2015 (4): 254-257. doi:10.1093/omcr/omv010. http://dx.doi.org/10.1093/omcr/omv010.
Abstract
Nervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood–brain barrier, as combination therapy to treat HER2–neu-positive breast cancer with brain metastases.
Description
Other Available Sources
Research Data
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service